|
Author Archive: AZBio
BIO Shares Member Perspectives on the use of Real World Evidence
As policy makers and regulators consider how best to incorporate the use of of real-world evidence (RWE) and real-world data (RWD) for changes to the label of an approved product, The Biotechnology Innovation Organization (BIO) has prepared a white paper to offer the perspectives of BIO member companies.Continue reading
Report Highlights Best Practices in Bioscience Economic Development
Every two years, the Biotechnology Innovation Organization (BIO) publishes a biennial BIO Economic Development Best Practices Report that catalogs state and regional economic development initiatives. The best practice examples contained within this report highlight the critical facets that foster high-performing industry and the long-term success it has maintained. The report reaffirms that successful industry development initiatives are built upon the following four key building blocks for company creation and expansion:Continue reading
Master of the immune system: Myxoma virus could solve long-standing medical conundrums
Virus: friend or foe? Viruses are likely the most abundant biological entities on Earth – they inhabit every ecosystem, and thus have shaped the evolution of most species. But we have been conditioned to believe that viruses only pose a threat to life. Until recently, viruses were only thought to be infectious agents that exist and replicate within the cells of a host organism, often causing life-threatening illnesses. Although this is true and much of modern healthcare is aimed at preventing infection at the hands of these pathogens, viruses can also be used to vanquish other diseases without any adverse health effects to the host.Continue reading
AbbVie Announces Plans to Acquire Allergan for $63 Billion
On June 25, 2019, AbbVie Inc. and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019.Continue reading
Pursing the Possible – Stephen Albert Johnston’s work featured on CNN
Is it possible to create a general cancer vaccine? Stephen Albert Johnston may find the answer with the help of man’s best friend.
Application Process Opens for New Life Science Incubator in Oro Valley
OVIL, the Oro Valley Innovation Lab, is now accepting applications for laboratory/office space before the facility opens in the spring of 2020. Continue reading
TGen Study: Individuals with Elevated Risk of Alzheimer’s Ma Show Memory Changes up to Four Decades before Typical Age of Onset
Lack of cure for dementia highlights need for early detection; early interventionContinue reading
Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference
Based on unmet medical need and encouraging data company will explore regulatory pathwaysContinue reading